# Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients

> **NCT01929408** · — · COMPLETED · sponsor: **Fred Hutchinson Cancer Center** · enrollment: 703 (actual)

## Conditions studied

- Acute Myeloid Leukemia (AML)
- Myelodysplastic Syndrome (MDS)

## Interventions

_None listed._

## Key facts

- **NCT ID:** NCT01929408
- **Lead sponsor:** Fred Hutchinson Cancer Center
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2013-07-19
- **Primary completion:** 2018-12-04
- **Final completion:** 2018-12-04
- **Target enrollment:** 703 (ACTUAL)
- **Last updated:** 2019-11-15

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01929408

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01929408, "Feasibility and Outcomes of Allogeneic HCT Compared to Chemotherapy in Older AML Patients". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01929408. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*